Established in the year 1924 in India GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is one of the oldest pharmaceuticals company and employs over 4,500 people. Globally, they are a £ 26.5 billion (US$ 39.14 billion), leading, research-based healthcare and pharmaceutical company. In India, they are one of the market leaders with a turnover of Rs 2,520.2 crore (US$ 402.37 million) and a share of 3.55 per cent. At GSK, our mission is to improve the quality of life by enabling people to do more, feel better and live longer. This mission drives us to make a real difference to the lives of millions of people with our commitment to effective healthcare solutions.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GSK OPENS NEW GLOBAL VACCINES R&D CENTRE IN US

GSK | December 16, 2016

news image

GlaxoSmithKline (GSK) has opened its new global vaccines research and development (R&D) centre in Rockville, Maryland, as part of plans to expand its vaccines presence in the US.The company will invest more than $50m in the next two years to continue to develop the site with new scientific research technology and equipment.The centre is expected to create up to 200 new jobs.GSK Vaccines president Luc Debruyne said: “Our investment here signifies our commitment to discovering and developing new v...

Read More

GSK INVESTS $139M TO BOOST LUPUS DRUG PRODUCTION

BioPharma Dive: Biotech and Pharma news | May 04, 2017

news image

GlaxoSmithKline will invest $139 million in its Rockville, Maryland manufacturing site, boosting production capacity for its lupus drug Benlysta (belimumab) in response to growing demand....

Read More

US FDA ISSUES CRL TO HIKMA’S GENERIC VERSION OF GSK’S ADVAIR DISKUS

pharmaceutical-technology | May 12, 2017

news image

Hikma Pharmaceuticals has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of its....

Read More

GSK WALKS AWAY FROM IONIS ANTISENSE DRUGS

GSK | August 14, 2017

news image

GlaxoSmithkline has turned down options to take on board Ionis Pharmaceuticals' experimental antisense therapies inotersen and IONIS-FB-LRx following a pipeline revamp. Inotersen is being developed for patients with TTR amyloidosis (ATTR), a rare disease caused by the build-up of amyloid within the tissues of the body damaging the structure and the function of the organs affected. Ionis said it recently completed a Phase III trial of inotersen demonstrating its “significant benefit” on both prim...

Read More
news image

GSK OPENS NEW GLOBAL VACCINES R&D CENTRE IN US

GSK | December 16, 2016

GlaxoSmithKline (GSK) has opened its new global vaccines research and development (R&D) centre in Rockville, Maryland, as part of plans to expand its vaccines presence in the US.The company will invest more than $50m in the next two years to continue to develop the site with new scientific research technology and equipment.The centre is expected to create up to 200 new jobs.GSK Vaccines president Luc Debruyne said: “Our investment here signifies our commitment to discovering and developing new v...

Read More
news image

GSK INVESTS $139M TO BOOST LUPUS DRUG PRODUCTION

BioPharma Dive: Biotech and Pharma news | May 04, 2017

GlaxoSmithKline will invest $139 million in its Rockville, Maryland manufacturing site, boosting production capacity for its lupus drug Benlysta (belimumab) in response to growing demand....

Read More
news image

US FDA ISSUES CRL TO HIKMA’S GENERIC VERSION OF GSK’S ADVAIR DISKUS

pharmaceutical-technology | May 12, 2017

Hikma Pharmaceuticals has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of its....

Read More
news image

GSK WALKS AWAY FROM IONIS ANTISENSE DRUGS

GSK | August 14, 2017

GlaxoSmithkline has turned down options to take on board Ionis Pharmaceuticals' experimental antisense therapies inotersen and IONIS-FB-LRx following a pipeline revamp. Inotersen is being developed for patients with TTR amyloidosis (ATTR), a rare disease caused by the build-up of amyloid within the tissues of the body damaging the structure and the function of the organs affected. Ionis said it recently completed a Phase III trial of inotersen demonstrating its “significant benefit” on both prim...

Read More